Alkasolv Uractiv Sachets
people prone to kidney stones.
Dosage and administration
Dissolve the content of each sachet in 150-300 ml water.
The product contains sucralose, a non-caloric sweetener; therefore it can be administered safely in diabetic patients.
-Keep out of the reach and sight of children.
-Store below 25°C, in the original packaging.
-Do not use after the expiry date stated on the package.
-Renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min.), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia.
–Patients with active urinary tract infection (with urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Alkasolv to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate.
–Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adynamia episodica hereditaria, extensive tissue breakdown as in severe burns, or the administration of a potassium sparing agent (such as trimaterene, spironolactone or amiloride).
–Patients with peptic ulcer disease because of its ulcerogenic potential.
-Patients with Uncontrolled diabetes, chronic cardiac deficiency (CCD) and Patients with sever diarrhea.
-Patients with high magnesium, and low sodium in the blood.
-Patients with hypersensitivity to any of the ingredients.
-Potassium-sparing diuretic (such as trimaterene, spironolactone or amiloride) should be avoided
–Alkasolv should be given to a pregnant woman only if clearly needed